Denosumab carries a marked risk of profound, refractory hypocalcemia in advanced chronic kidney disease, particularly stages 4 to 5D and comorbid CKD-mineral and bone disorder. In these patients, impaired calcitriol synthesis and secondary hyperparathyroidism render systemic calcium homeostasis acutely dependent on continuous skeletal resorption. Rapid RANK-ligand inhibition abruptly halts osteoclastic efflux, precipitating dangerous calcium nadirs typically occurring two to ten weeks post-injection. Severe cases carry documented risks of lethal arrhythmias, seizures, and exacerbation of adynamic bone disease. Clinical management mandates rigorous pre-treatment evaluation of baseline mineral metabolism, aggressive replete therapy with calcitriol and calcium salts, and frequent post-dose biochemical surveillance.

Mild autonomous cortisol secretion, or MACS, represents subtle hypothalamic-pituitary-adrenal axis dysregulation most frequently encountered during the workup of adrenal incidentalomas. Defined primarily by a post-one-milligram dexamethasone suppression test cortisol level exceeding 1.8 micrograms per deciliter in the absence of overt Cushingoid physical features, this biochemical state lacks classic signs but carries significant cardiometabolic morbidity. Pathophysiologically, sustained low-grade hypercortisolemia exacerbates insulin resistance, hypertension, dyslipidemia, and vertebral skeletal fragility. Clinical management hinges on individualized risk stratification: optimizing medical therapy for metabolic and bone complications while evaluating unilateral laparoscopic adrenalectomy for younger patients or those with rapidly progressing, refractory metabolic comorbidities.